Advertisement
Advertisement

CRBU

CRBU logo

Caribou Biosciences, Inc. Common Stock

1.41
USD
Sponsored
-0.07
-5.07%
Jan 30, 15:56 UTC -5
Closed
exchange

After-Market

1.41

0.00
+0.36%

CRBU Earnings Reports

Positive Surprise Ratio

CRBU beat 12 of 18 last estimates.

67%

Next Report

Date of Next Report
Mar 02, 2026
Estimate for Q4 25 (Revenue/ EPS)
$2.66M
/
-$0.32
Implied change from Q3 25 (Revenue/ EPS)
+21.12%
/
+6.67%
Implied change from Q4 24 (Revenue/ EPS)
+28.18%
/
-17.95%

Caribou Biosciences, Inc. Common Stock earnings per share and revenue

On Nov 12, 2025, CRBU reported earnings of -0.30 USD per share (EPS) for Q3 25, beating the estimate of -0.36 USD, resulting in a 18.37% surprise. Revenue reached 2.20 million, compared to an expected 2.87 million, with a -23.49% difference. The market reacted with a -12.17% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 analysts forecast an EPS of -0.32 USD, with revenue projected to reach 2.66 million USD, implying an increase of 6.67% EPS, and increase of 21.12% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, Caribou Biosciences, Inc. Common Stock reported EPS of -$0.30, beating estimates by 18.37%, and revenue of $2.20M, -23.49% below expectations.
The stock price moved down -12.17%, changed from $2.26 before the earnings release to $1.99 the day after.
The next earning report is scheduled for Mar 02, 2026.
Based on 9 analysts, Caribou Biosciences, Inc. Common Stock is expected to report EPS of -$0.32 and revenue of $2.66M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement